NASDAQ · INMD
Healthcare · Medical - Devices
$14.99
Down-$0.03 (-0.20%)
Updated Aug 19, 2026, 7:49 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
INMD closed at $14.99 after 21 trading sessions, down 2.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $15.06 | $15.09 | $14.94 | $14.99 | 375.9K |
| Aug 17, 2026 | $15.13 | $15.15 | $14.96 | $15.02 | 548.99K |
| Aug 14, 2026 | $15.25 | $15.31 | $15.10 | $15.15 | 350.55K |
| Aug 13, 2026 | $15.30 | $15.38 | $15.085 | $15.20 | 347.69K |
| Aug 12, 2026 | $15.02 | $15.28 | $15.02 | $15.23 | 358.41K |
| Aug 11, 2026 | $15.21 | $15.34 | $15.12 | $15.14 | 355.43K |
| Aug 10, 2026 | $15.21 | $15.255 | $15.1214 | $15.19 | 459.78K |
| Aug 7, 2026 | $15.10 | $15.355 | $15.09 | $15.31 | 397.22K |
| Aug 6, 2026 | $15.24 | $15.2899 | $15.06 | $15.12 | 498.72K |
| Aug 5, 2026 | $14.97 | $15.312 | $14.97 | $15.21 | 533.62K |
| Aug 4, 2026 | $15.33 | $15.385 | $15.24 | $15.37 | 359.2K |
| Aug 3, 2026 | $15.29 | $15.395 | $15.255 | $15.35 | 394.62K |
| Jul 31, 2026 | $15.09 | $15.19 | $14.995 | $15.14 | 472.63K |
| Jul 30, 2026 | $15.15 | $15.15 | $14.94 | $15.095 | 682.34K |
| Jul 29, 2026 | $15.38 | $15.51 | $14.98 | $15.15 | 866.66K |
| Jul 28, 2026 | $15.27 | $15.60 | $15.27 | $15.47 | 586.15K |
| Jul 27, 2026 | $15.25 | $15.565 | $15.21 | $15.38 | 688.61K |
| Jul 24, 2026 | $15.16 | $15.35 | $15.11 | $15.17 | 419.2K |
| Jul 23, 2026 | $15.19 | $15.19 | $14.99 | $15.09 | 536.87K |
| Jul 22, 2026 | $15.36 | $15.36 | $15.16 | $15.20 | 373.55K |
| Jul 21, 2026 | $15.365 | $15.395 | $15.2001 | $15.36 | 387.93K |
The latest Smart Investors Daily articles mentioning INMD.
INMD research
Company profile and research snapshot.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 7, 2026 | Barclays | Overweight | — |
| May 7, 2026 | Baird | Neutral | — |
| Dec 17, 2025 | Canaccord Genuity | Hold | — |
| Nov 6, 2025 | UBS | Neutral | — |
| Oct 10, 2025 | Needham | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
https://www.sec.gov/Archives/edgar/data/1742692/000117891326004040/zk2635934.htm
SeekingAlpha · Aug 8, 2026
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
ChartMill · Aug 5, 2026
InMode Q2 revenue of $95.6M matches estimates, EPS beats at $0.35; shares slip 2.5% as growth stays flat.
Yahoo · Aug 5, 2026
InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INMD.
